Navigation Links
3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
Date:1/28/2008

SHENYANG, China, Jan. 28 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Kevin Teo to the position of Chief Financial Officer effective January 28, 2008. Mr. Teo will replace Clara Mak, who is resigning for personal reasons. To assist with the transition, Ms. Mak will stay on with the Company until February 29, 2008.

Dr. Jing Lou, CEO of 3SBio, commented, "I am pleased to welcome Kevin Teo to 3SBio's senior management team. After a focused search, Kevin emerged as the clear choice to fill the role of Chief Financial Officer at 3SBio, as he brings with him a wealth of experience in finance and accounting with some of the leading companies in the region. I have full confidence in Kevin's ability to transition smoothly into the role of the CFO of 3SBio, and we look forward to his contributions and leadership as we continue to build 3SBio into the leading biotech company in China. Clara Mak, who has been an integral part of the team, has led 3SBio through the IPO process and on to continued growth as a public company. Her financial leadership has also been instrumental in helping the company successfully position itself for continued solid performance and she will be missed. We wish her the best in her future endeavors."

Mr. Teo, 42, brings to 3SBio over 20 years of relevant experience, having held a number of senior finance and accounting positions in the energy and technology industries throughout Asia. Most recently, he served as Group Business Controller at East Asia Power (Xiamen), where he oversaw and managed finance and accounting teams located in Hong Kong, Singapore, Jakarta, Xiamen, Nanjing and Beijing. His responsibilities included, but were not limited to, the implementation of company-wide internal control procedures and policies, oversight of the company's monthly financial statements and position, liaison with corporate departments, interaction with external parties and advisors, and coordination of annual audits at subsidiary and group levels.

Prior to his employment with East Asia Power (Xiamen), Mr. Teo held senior roles at Huawei Technologies Co. Ltd. (Shenzhen), Siemens Malaysia Sdn. Bhd., Siemens Cerberus Sdn. Bhd., Wetlands International - Asia Pacific, Chua Song Seng Sdn. Bhd., and Anuarul Azizan Chew & Co. Mr. Teo received a London Chamber of Commerce and Industry Third Level Group Diploma in Cost Accounting and a Pitman Certificate in Advanced Accounting in 1989. He is also a member of the Association of Chartered Certified Accountants since 1995 and received a certificate in International Financial Reporting Standards in 2006. He attended the Master of Laws in International Business Law accredited by School of Law, Staffordshire University in the U.K. He has been a member of the Malaysian Institute of Accountants since 1996.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .

For more information, please contact:

Investor Contact:

Clara Mak, CFO

3SBio Inc.

Tel: +86-24-2581-1820

Investor Relations(HK):

Ruby Yim

Taylor Rafferty

Tel: +852-3196-3712

Investor Relations(US):

Mahmoud Siddig

Taylor Rafferty

Tel: +1-212-889-4350

Media Contact:

John Dooley

Taylor Rafferty

Tel: +1-212-889-4350


'/>"/>
SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
2. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
3. 3SBio Inc. to Hold Annual General Meeting
4. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
5. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
6. Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic
7. Hoya Announces Third Quarter and Nine Month Results for 2007
8. Medefield Announces New Appointments to North American Business Unit
9. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
10. US Oncology Announces Realignment of Executive Team
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... The Board of ... appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from ... founding commercial leaders responsible for the commercialization of multiple orphan drug indications. ...
(Date:4/27/2016)... ... 27, 2016 , ... A compact PET scanner called NuPETâ„¢ ... (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and MRI are complementary ... subjects. Simultaneous PET/MRI imaging offers a solution to many challenges that face researchers ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... ... April 26, 2016 , ... BaseHealth , ... joined the company as Chief Business Officer. Arianpour, a genomics pioneer and visionary ... market, was most recently Chief Commercial Officer of Pathway Genomics. He has held ...
Breaking Biology Technology:
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
(Date:3/15/2016)... 2016 Yissum Research Development Company of ... of the Hebrew University, announced today the formation of ... of various human biological indicators. Neteera Technologies has completed ... private investors. ... of electromagnetic emissions from sweat ducts, enables reliable and ...
(Date:3/10/2016)... PUNE, India , March 10, 2016 ... to a new market research report "Identity and Access ... SSO, & Audit, Compliance, and Governance), by Organization Size, ... Forecast to 2020", published by MarketsandMarkets, The market is ... to USD 12.78 Billion by 2020, at a Compound ...
Breaking Biology News(10 mins):